Prosztatarák: vizsgálatok itt: Németország
97 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 18.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- Where
- Berlin, Bonn, Dresden, Erlangen, Essen, Hamburg, Heidelberg, Jena, Kiel, Ulm, Würzburg
- Életkor
- 18 év and over
- People
- 750 worldwide
- Run by
- Amgen
See details and how to joinNCT07213674 - No phaseNot yet taking people in NémetországA Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice
- Where
- Many Locations
- Életkor
- 18 év and over
- People
- 1600 worldwide
- Run by
- Bayer
See details and how to joinNCT07344779 - 3. fázisNot yet taking people in NémetországAZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
- Where
- Augsburg, Berlin, Bonn, Cologne, Dresden, Essen, Jena, Karlsruhe, München, Münster, Nuremberg, Rostock, Stuttgart, Tübingen, Würzburg
- Életkor
- 18 év and over
- People
- 670 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07611110 - 1/2. fázisNot yet taking people in NémetországA study of benfo‑oxythiamine added to Pluvicto® in adults with advanced prostate cancer whose disease is stable after two prior Pluvicto® cycles
- Where
- Essen, Muenster, Munich
- Életkor
- 18 év and over
- People
- 48
- Run by
- Benfovir AG
See details and how to join2026-527059-25-00 - 2. fázisNot yet taking people in NémetországA study comparing Pluvicto® plus Standard of Care treatment with ADT and Nubeqa® vs. Standard of Care treatment with ADT and Nubeqa® in Patients with mHSPC
- Where
- Freiburg im Breisgau
- Életkor
- 18 év and over
- People
- 72
- Run by
- Medical Center - University Of Freiburg
See details and how to join2026-525520-20-00 - 1/2. fázisTaking peopleA Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
- Where
- Dresden, Essen, München, Stuttgart
- Életkor
- 18 év and over
- People
- 123 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07226986 · EU 2025-521859-23-00 - 3. fázisNot yet taking people in NémetországSaruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
- Where
- Bergisch Gladbach, Berlin, Bonn, Dresden, Duisburg, Essen, Frankfurt Am Main, Hamburg, Heidelberg, Herne, Mannheim, Mettmann, Muenster, Munich, Nuremberg, Rostock, Ulm
- Életkor
- 18 év and over
- People
- 1330 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07711002 · EU 2026-526275-38-00 - 3. fázisTaking peopleA Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
- Where
- Augsburg, Berlin, Braunschweig, Cologne, Dresden, Duesseldorf, Duisburg, Essen, Giessen, Goettingen, Gronau (Westf.), Hamburg, Herne, Luebeck, Marburg, Muenster, Nuertingen, Nuremberg, Regensburg, Schwerin, Trier, Ulm, Wuerzburg
- Életkor
- 18 év and over
- People
- 700 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06952803 · EU 2024-513586-39-00 - 3. fázisFut, nem toborozThis Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
- Where
- Berlin, Duesseldorf, Goettingen, Hamburg, Heidelberg, Luebeck, Mettmann, Muenster, Nuertingen, Regensburg, Tuebingen, Ulm
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Pfizer
See details and how to joinNCT07028853 · EU 2024-519369-24-00 - 1/2. fázisNot yet taking people in NémetországPhase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
- Where
- Essen, Jena, Rostock, Tübingen
- Életkor
- 18 év to 99 év
- People
- 152 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07590934 - 1/2. fázisFut, nem toborozA Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- Where
- Hamburg, Heidelberg, Jena, Ulm
- Életkor
- 18 év and over
- People
- 360 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06863272 · EU 2024-516036-94-00 - 1/2. fázisNot yet taking people in NémetországAn Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
- Where
- Duesseldorf, Jena
- Életkor
- 18 év and over
- People
- 188 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07206056 · EU 2025-521880-10-00 - 2. fázisNot yet taking people in NémetországMulti-peptide Vaccination and Bispecific PSMAxCD3 Antibody Treatment in Patients With Prostate Cancer
- Where
- Berlin, Essen, Heidelberg, Tuebingen
- Életkor
- 18 év to 80 év
- People
- 84
- Run by
- University Hospital Tuebingen
See details and how to joinNCT07860047 · EU 2025-522144-41-00 - 1/2. fázisVisszavonvaStudy of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Where
- Bayern, Berlin, Heidelberg, Mainz
- Életkor
- 18 év to 130 év
- People
- 695 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05417594 · EU 2023-504984-17-00 - 1/2. fázisTaking peopleThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Where
- Augsburg, Essen, Frankfurt am Main, Hamburg, Heidelberg
- Életkor
- 12 év and over
- People
- 300 worldwide
- Run by
- PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750 - 1. fázisTaking peopleStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Where
- Essen, Heidelberg, Herne, Jena, Nuertingen, Tuebingen
- Életkor
- 18 év and over
- People
- 1394 worldwide
- Run by
- Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00 - 2. fázisVisszavonvaStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Where
- Berlin, Essen, Hanover, München, Regensburg
- Életkor
- 18 év to 130 év
- People
- 454 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00 - 1. fázisNot yet taking people in NémetországPhase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
- Where
- Essen, Munich
- Életkor
- 18 év to 100 év
- People
- 116 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07006727 · EU 2024-519111-34-00 - No phaseTaking peopleTo Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.
- Where
- Essen
- Életkor
- 18 év and over
- People
- 850 worldwide
- Run by
- XEOS Medical
See details and how to joinNCT06970275 - No phaseTaking peopleDaily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer
- Where
- Homburg, Stuttgart
- Életkor
- 18 év and over
- People
- 132 worldwide
- Run by
- Varian, a Siemens Healthineers Company
See details and how to joinNCT05804318 - 3. fázisTaking people[18F]PSMA-1007 PET CT in patients with newly-diagnosed prostate cancer
- Where
- Dresden, Duesseldorf, Gronau (Westf.), Hamburg, Leipzig, Muenster, Munich, Rostock
- Életkor
- 18 év and over
- People
- 355 worldwide
- Run by
- Abx Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GmbH
See details and how to join2023-504026-19-01 - 1. fázisTaking peopleA study to test a new drug (TRP-001) given before prostate cancer surgery in patients with very high-risk Prostate cancer.”
- Where
- Cologne
- Életkor
- 18 év and over
- People
- 18
- Run by
- Torpedo Pharmaceuticals AG
See details and how to join2026-526406-32-00 - 2. fázisFut, nem toborozA Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
- Where
- Heinsberg, Nuertingen
- Életkor
- 18 év and over
- People
- 218 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT07005154 · EU 2024-517653-27-00 - No phaseCsak meghívásosRegisterPROS - A Registry for Prostate Cancers
- Where
- Münster
- Életkor
- 45 év to 100 év
- People
- 1000
- Run by
- Wren Laboratories LLC
See details and how to joinNCT06872619 - 1. fázisFut, nem toborozEvaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
- Where
- Essen, Hamburg
- Életkor
- 18 év to 64 év
- People
- 40 worldwide
- Run by
- Amgen
See details and how to joinNCT06613100 · EU 2024-511965-13-00